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Abstract 
Purpose: The aim of this study was to assess the 6-months dysphagia-free survival, improvement 
in swallowing function, complication rate, and overall survival in patients with incurable esophageal 
cancer treated with palliative radiotherapy. 
Methods: We retrospectively reviewed data from 139 patients (median age 72 years) with ad-
vanced/recurrent incurable esophageal cancer, who were referred to 3 German radiation on-
cology centers for palliative radiotherapy between 1994 and 2014. Radiotherapy consisted of 
external beam radiotherapy (EBRT) with 30 - 40.5 Gy/2.5 - 3 Gy per fraction, brachytherapy alone 
(BT) with 15 - 25 Gy/5 - 7Gy per fraction/weekly and EBRT + BT (30 - 40.5 Gy plus 10 - 14 Gy 
with BT) in 65, 46, and 28 patients, respectively. Dysphagia-free survival (Dy-PFS) was defined as 
the time to worsening of dysphagia for at least one point, a new loco-regional failure or death of 
any cause. 
Results: Median follow-up time was 6 months (range 1-6 months). Subjective symptom relief was 
achieved in 72 % of patients with median response duration of 5 months. The 1-year survival rate 
was 30%. The 6-months Dy-PFS time for the whole group was 73 ± 4%. The 6-months Dy-PFS was 
90 ± 4% after EBRT, 92 ± 5% after EBRT + BT and 37 ± 7% after BT, respectively (p<0.001). Five 
patients lived for more than 2 years, all of them were treated with EBRT ± BT. Ulceration, fistula 
and stricture developed in 3, 6 and 7 patients, respectively.  
Conclusions: Radiotherapy leads to symptom improvement in the majority of patients with 
advanced incurable esophageal cancer. The present results favor EBRT ± BT over BT alone. Due to 
the retrospective nature of this study, imbalances in baseline characteristics might have contrib-
uted to this finding, and further trials appear necessary. 
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Introduction 
More than 50% of esophageal cancer patients 
present with locally advanced stage or distant metas-
tases with tumor related symptoms and/or poor 
general condition [1, 2]. The most common can-
cer-related complication in these patients is dysphagia 
with an increasing rate as the disease progresses, 
leading to nutritional compromise, pain, reduced 
performance status and deterioration of quality of life 
[3, 4]. Many of these patients with severe clinical 








section or curative radiochemotherapy [5, 6]. The lat-
ter approaches are not suitable for patients with dis-
tant metastases either [7]. In symptomatic patients, 
long-term palliation of dysphagia is an important goal 
of therapy. Various palliative treatment modalities 
have been used in an attempt to relieve dysphagia 
and improve quality of life for the remaining life time. 
These include stent placement, dilation, external beam 
radiation therapy (EBRT), brachytherapy, chemo-
therapy, laser treatment, photodynamic therapy or 
ablation [8, 9]. Of those approaches endoluminal 
stenting, radiation therapy, or a combination of both 
are most commonly used [10]. Esophagectomy for 
palliation is not recommended due to the associated 
high morbidity and mortality rate. Thermal and 
chemical ablative therapies provide acceptable dys-
phagia palliation but have an increased requirement 
for re-interventions and for adverse effects. Chemo-
therapy alone for symptom relief might be possible in 
some patients, but it takes several weeks to achieve 
this effect. Patients in poor general condition are not 
fit enough to undergo effective chemotherapy [11]. 
Development of distant metastases during the course 
of disease is common. Thus, oncologists often chose 
local treatment options for relief of initial local 
symptoms and postpone chemotherapy for the 
treatment of systemic disease. Radiotherapy is a po-
tent local treatment option, which can provide 
symptom relief and prolongation of survival. Its ef-
fects were the subject of the present retrospective 
study. The primary endpoint of the study was the 
6-month dysphagia progression-free survival (6-mo 
Dy-PFS). Secondary endpoints were overall survival, 
time to relapse of dysphagia to the pretreatment sta-
tus (or worse), time to worsening of dysphagia by at 
least one point, and complication rate.  
Methods and Material 
Patients 
We retrospectively reviewed data from 189 pa-
tients with advanced/recurrent esophageal cancer, 
who were referred to one of three German radiation 
oncology centers (Bochum, Herne, Witten) for pallia-
tive radiotherapy from 1994 to 2014. Patients with 
histologically confirmed squamous cell or adenocar-
cinoma of the esophagus, considered too advanced or 
medically unsuitable for radical treatment (with or 
without metastatic disease), symptomatic with dys-
phagia score of 1-4 (0= no dysphagia, Table 1) were 
eligible. Patients were excluded for the following 
reasons: previous radiochemotherapy, presence of an 
esophageal fistula, simultaneous other primary can-
cer. One-hundred thirty nine patients fulfilled the 
inclusion criteria and were enrolled in this study. Pa-
tients’ characteristics are summarized in Table 2. The 
pre-treatment evaluation included a medical history 
and physical examination, complete blood count, 
computed tomography of the neck/chest/abdomen 
and an esophagogastroscopy and endosonography, if 
technically possible. A bronchoscopy was carried out 
if there was a suggestion on computed tomography or 
clinical evidence of airway involvement. 
 
Table 1. Dysphagia scoring scale 
0 Able to consume a normal diet 
1 Dysphagia with certain solid foods 
2 Able to swallow semi-solid soft foods 
3 Able to swallow liquids only 
4 Unable to swallow saliva (complete dysphagia) 
 
Table 2. Characteristics of all patients 
Characteristics No. (%) All patients 
N= 139 
 
Gender   
Female 31 (22)  
Male 108 (78)  
Age, mean (range), y 70 (48-85)  
Histology   
Squamous cell carcinoma 101 (73)  
Adenocarcinoma 38 (27)  
Localisation   
Suprabifurcal  60 (43)  
Infrabifurcal 48 (35)  
Overlapping 31 (22)  
Length   
≤8 cm 122 (88)  
>8cm 17 (12)  
Lymph node metastases, cN+   
Yes 116 (84)  
No 23 (17)  
ECOG-PS at palliative treatment   
0-1  39 (28)  
2-3  100 (72)  
Treatment   
EBRT 65 (47)  
BT 46 (33)  
EBRT+BT 28 (20)  
Dysphagia score    
0  0 (0)  
1 42 (30)  
2 60 (43)  
3 30 (22)  
4 7 (5)  
ECOG-PS: Eastern Cooperative Oncology Group performance status; EBRT: ex-
ternal beam radiotherapy; BT: brachytherapy 
 
Treatment 
Radiotherapy consisted of EBRT with 
30-40.5 Gy/2.5-3 Gy per fraction, 5 days a week in 65 
patients. The target volume consisted of the primary 
esophageal tumor with margins of 1 - 3 cm in the cra-
nial caudal direction and 1 cm circumferentially. En-
doluminal treatment was administered by a high dose 
rate (HDR) afterloading device with an iridium192 




source. For the treatment a blind ending gastric tube 
of 10 mm was passed through the tumor stenosis. The 
applicator with a centimeter scaled dummy chain for 
determination of the irradiated length was then in-
serted. The irradiation length included the tumor 
stenosis with a safety margin of 1-2 cm above and 
below. The single dose of each HDR treatment was 5-7 
Gy specified to 1 cm from the applicator surface. 
Brachytherapy (BT) alone was performed in 46 pa-
tients with a total dose of 15-25 Gy/5 Gy per frac-
tion/weekly (Table 3). Twenty-eight patients under-
went EBRT (30 - 40 Gy) plus 1 to 3 fractions of BT with 
a dose of 5 - 7 Gy per fraction/weekly. A stent was 
placed in 18 patients prior to and in 25 patients after 
radiotherapy. Chemotherapy was administered to 18 
patients prior to and 39 patients after radiotherapy.  
Table 3. Baseline characteristics for different treatment groups 




BT EBRT BT+EBRT p 
Gender   
Female 31 (22) 8 (17) 18 (28) 5 (18) 0.426 
Male 108 (78) 38 (83) 47 (72) 23 (82) 
Age, Median 
(range) 
72 (48-85) 73 (61-85) 69 (57-81) 69 (48-81) <0.001 
ECOG-PS   
0-I  39 (28) 8 (17) 21 (32)  10 (36) 0.130 
II-III  100 (72) 38 (82) 44 (68) 18 (64) 
Tumor length  
1-8cm 122 (88) 36 (87) 59 (91) 27 (93) 0.55 
>8cm 17 (12) 10 (22) 6 (9) 1 (7) 
ECOG-PS: Eastern Cooperative Oncology Group performance status; EBRT: ex-
ternal beam radiotherapy; BT: brachytherapy 
 
Dysphagia scoring, follow-up and toxicity 
analysis 
Dysphagia was measured on a five-point dys-
phagia scale (Table 1). Acute treatment-related tox-
icity was graded according to the National Cancer 
Institute’s Common Terminology Criteria for Adverse 
Events, version 3.0 (CTC 3.0), except for dysphagia. 
For the dysphagia, the above mentioned dysphagia 
score was used. Patients were assessed weekly during 
the treatment and each 2 - 4 weeks thereafter. At week 
8-10, all patients underwent a reassessment of the 
local disease with either an endoscopy and/or CT. 
This was repeated at the time of dysphagia progres-
sion to confirm whether progression was secondary to 
disease or stricture. After finishing radiotherapy pa-
tients were followed for six months until symptomatic 
or luminal disease progression, and every 2 months 
thereafter if clinically feasible. At each visit, patients 
were assessed with a medical history, physical ex-
amination, dysphagia score, toxicity score, weight and 
performance status (PS).  
Statistical methods 
Statistical analyses were performed using the 
SPSS software (version 20.0). Overall survival (OS) 
was defined as death from any cause, dysphagia-free 
survival (Dy-PFS) was defined as the time to wors-
ening of dysphagia by at least one point, loco-regional 
failure or death of any cause.  
All time estimates began with the 1st day after 
start of radiation therapy to the date of first failure or 
the date of last clinical visit, whichever occurred first. 
OS and PFS probabilities were estimated using 
Kaplan-Meier analysis. Unadjusted associations be-
tween continuous variables and toxicities ≥ grade 2 
were assessed by Wilcoxon Rank-Sum test or Krus-
kal-Wallis test. Unadjusted associations between cat-
egorical variables and toxicities were assessed by 
Fisher’s exact test. 
Results 
Median follow-up time was 6 months (range 1-6 
months). A dysphagia score of 1, 2, 3 or 4 was ob-
served in 30%, 43%, 22% and 5% of patients at the 
start of the treatment, respectively. Longitudinal 
changes are displayed in Figures 1-3. The 6-months 
Dy-PFS probability for the whole group was 73 ± 4% 
(Fig. 4). The 6-months Dy-PFS was 90 ± 4% after 
EBRT, 92 ± 5% after EBRT + BT and 37 ± 7% after BT, 
respectively (p<0.001, Fig. 5). Subjective symptom 
relief was achieved in 72% of all patients with median 
response duration of 5 months. The median time pe-
riod to dysphagia improvement for at least one point 
was 26 weeks for patients who were treated with 
EBRT ± BT and 16 weeks for patients who were 
treated with BT alone (Fig. 2-3). A worsening back to 
the initial dysphagia score or worse was observed in 
35% after BT, 8% after EBRT and 7% after EBRT + BT, 
respectively. The 1- and 2-year OS rates were 30 ± 4% 
and 4 ± 2%, respectively with a median overall sur-
vival time of 10 months (Fig. 6). Five patients lived 
more than 2 years, all of them were treated with 
EBRT ± BT.  
Treatment sequelae 
There were no grade 5 toxicities. Mucositis 
≥grade 2 (39%), temporary worsening of general con-
dition (29%) and temporary increase of pain (25%) 
were the most common acute toxicities of the treat-
ment. Bacterial pneumonia and hematologic toxicity 
≥grade 2 were observed in 6% and 4% of the patients, 
respectively. There were 3 ulcerations in the context of 
persistent or recurrent tumor, 2 patients were treated 
with stent + EBRT and 1 with induction chemothera-
py + BT. In 6 patients a fistula formation was ob-
served, 2 were treated with BT, 3 with stent + EBRT 
and 1 patient with induction chemotherapy + stent + 
EBRT. In 7 patients esophageal strictures were ob-
served, requiring repeated bouginage.  






Fig 1. Changes in dysphagia score over time in all patients. 
 
Fig 2. Changes in dysphagia score over time in the brachytherapy group. 
 
Fig 3. Changes in dysphagia score over time in the EBRT ± brachytherapy group. 
 





Fig. 4 Kaplan-Meier curves for dysphagia progression free survival in the 
whole cohort. 
 
Fig. 5 Kaplan-Meier curves for dysphagia progression free survival in the 
subgroups. 
 
Fig. 6 Kaplan-Meier curves for overall survival in the whole cohort 
Discussion 
We report our multicenter 20-year experience 
with 139 incurable esophageal cancer patients treated 
for symptom relief with palliative RT. The overall 
treatment concept was individualized and included 
various combinations of stent placement, chemo-
therapy, and RT. Performance status, local tumor ex-
tension/obstruction, distant metastases and comor-
bidity were assessed before the overall concept was 
chosen. The optimal treatment regimen for palliation 
of dysphagia in locally advanced esophageal cancer is 
still controversially discussed [12]. However, effective 
symptom relief has been reported in many random-
ized and non-randomized clinical trials. It has been 
shown that stent placement alone was inferior to stent 
plus BT and stent loaded with radioactive seeds [13, 
14]. A further randomized trial (n=84 patients) com-
pared stent alone to stent and EBRT, 30 Gy in 10 frac-
tions [15]. Dysphagia scores improved significantly in 
both groups following stent insertion. However, 
dysphagia relief was more sustained after additional 
EBRT (7 vs. 3 months, p = 0.002). Overall median sur-
vival was significantly longer after additional EBRT 
(180 vs. 120 days, p = 0.009). There was no treat-
ment-related mortality, and the incidence of compli-
cations was similar in the two groups. A fourth ran-
domized study (n=219 patients) examined whether 
the combination of HDR BT and EBRT is superior to 
HDR BT alone for the palliation of esophageal cancer 
[16]. All patients received two fractions of HDR BT 
within 1 week (8 Gy prescribed at 1cm from source 
center). Patients randomized to EBRT received 30 Gy 
in 10 fractions. The primary outcome was dyspha-
gia-relief experience (DRE). Median survival was 6 
months (18% survival rate at 1 year). DRE was signif-
icantly improved with combined therapy, for an ab-
solute benefit of +18% at 200 days from randomiza-
tion (p = 0.019). In longitudinal regression analyses, 
scores for dysphagia, odynophagia, regurgitation, 
chest pain and performance status were all signifi-
cantly improved. In contrast, weight, toxicities and 
overall survival were not different between study 
arms. Together, these data from 4 individual studies 
suggest that combined therapy with stent + BT, stent 
+ EBRT or BT + EBRT is well tolerated and relatively 
safe. Yet not all possible combinations have been 
compared in randomized trials. 
Patients with distant metastatic stage IVB 
esophageal cancer with dysphagia due to the primary 
lesion might best be treated with chemotherapy plus 
local measures [17]. The authors investigated 40 pa-
tients. Treatment consisted of two courses of chemo-
therapy (5-fluorouracil and cisplatin) and concurrent 
irradiation of 40 Gy in 20 fractions to the esophageal 
primary tumor. Dysphagia score improved in 75% of 




the patients. Seventeen of the 20 patients (85%) who 
had required nutritional support at baseline improved 
their oral intake to no longer need the support, in a 
median time of 43 days. Disease control rate of the 
primary lesion was 95%, including 12 patients (30%) 
who achieved a complete response. The median sur-
vival was 10 months, and the 1-year-survival rate was 
45%. Major toxicities (grade 3 or 4) involved hemo-
globin (23%), leukocytes (15%), neutrophils (20%), 
anorexia (10%), nausea (3%), esophageal perforation 
(5%) and febrile neutropenia (3%). Two patients (5%) 
died within 30 days of terminating radiotherapy. 
Murray et al. performed a retrospective study, 
which shares important similarities with ours [18]. 
They analyzed data from 148 patients with histologi-
cally proven esophageal cancer, who were unsuitable 
for radical treatment (2005-2010). The median age of 
their patients was 74 years (range, 31-91). Forty-nine 
percent of patients were WHO PS 2 or 3, 70% had 
adenocarcinoma (only 27% in our study), 58% had 
locally advanced disease, and 28% had metastatic 
disease. Ninety-three percent of patients complained 
of dysphagia prior to radiotherapy, and 6% had a 
stent placement. Eighty-nine percent of patients re-
ceived a 2-D planned dose of 20 Gy in 5 fractions, i.e. a 
significantly lower dose than in most other studies 
discussed here, also in terms of biologically effective 
dose. Following radiotherapy, 75% of patients expe-
rienced an improvement in dysphagia and 25% of 
patients gained weight. Dy-PFS was not analyzed. 
Twenty-six percent of patients required subsequent 
insertion of an esophageal stent and a further 3% re-
ceived retreatment with radiotherapy. The median 
stent (and retreatment)-free survival was 4.9 months. 
In our study 18% of patients had subsequent stent 
insertion and median response duration after RT was 
5 months. Murray et al. reported median overall sur-
vival of 6.1 months (1-year survival 29%), compared 
to 10 months (30%). These data suggest that 
short-course radiotherapy could be considered in pa-
tients with limited survival expectation, e.g. those 
with poor PS and/or widespread metastatic disease. 
Important caveats exist regarding inter-study com-
parisons, because inhomogeneous populations were 
included, comprised of patients with or without dis-
tant metastases, good or poor PS etc. Limitations re-
garding our own study also include patient selection 
for the different treatment modalities and group sizes. 
In line with the randomized IAEA study in squamous 
cell cancer [16], our data suggest that BT alone might 
not be the preferred RT option. Excellent palliation 
rates were observed after EBRT with or without BT, 
i.e. 6-months Dy-PFS of 90 ± 4% after EBRT and 
92 ± 5% after EBRT + BT. A worsening back to the 
initial dysphagia score or worse was uncommon (8% 
after EBRT and 7% after EBRT + BT, compared to 35% 
after BT alone).  
Conclusion 
Radiotherapy leads to symptom improvement in 
about 70% of patients with esophageal cancer. Con-
sidering longer symptoms relief period and progres-
sion-free survival EBRT ± BT appears superior to BT 
alone. However, the present results were not obtained 
in the context of a randomized trial. 
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